Evidence map›Paper›PMID 28623900›Full record

ArticleBMC cancer2017

Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.

Junzheng Yang, Yilan Zhou, Shu-Kay Ng, Kuan-Chun Huang, Xiaoyan Ni, Pui-Wah Choi, Kathleen Hasselblatt, Michael G Muto, William R Welch, Ross S Berkowitz and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Junzheng YangDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Yilan ZhouDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Shu-Kay NgSchool of Medicine and Menzies Health Institute Queensland, Griffith University, QLD, Nathan, 4111, Australia.
Kuan-Chun HuangDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Xiaoyan NiDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Pui-Wah ChoiDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Kathleen HasselblattDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Michael G MutoDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
William R WelchDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Ross S BerkowitzDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Shu-Wing NgDepartment of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, 02115, USA. sng@partners.org.ORCID http://orcid.org/0000-0001-6814-0825
Brigham and Women's Hospital · USGriffith University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is the leading cause of death among gynecologic diseases in Western countries. We have previously identified a miR-200-E-cadherin axis that plays an important role in ovarian inclusion cyst formation and tumor invasion. The purpose of this study was to determine if the miR-200 pathway is involved in the early stages of ovarian cancer pathogenesis by studying the expression levels of the pathway components in a panel of clinical ovarian tissues, and fallopian tube tissues harboring serous tubal intraepithelial carcinomas (STICs), a suggested precursor lesion for high-grade serous tumors.

methodsRNA prepared from ovarian and fallopian tube epithelial and stromal fibroblasts was subjected to quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) to determine the expression of miR-200 families, target and effector genes and analyzed for clinical association. The effects of exogenous miR-200 on marker expression in normal cells were determined by qRT-PCR and fluorescence imaging after transfection of miR-200 precursors.

resultsOvarian epithelial tumor cells showed concurrent up-regulation of miR-200, down-regulation of the four target genes (ZEB1, ZEB2, TGFβ1 and TGFβ2), and up-regulation of effector genes that were negatively regulated by the target genes. STIC tumor cells showed a similar trend of expression patterns, although the effects did not reach significance because of small sample sizes. Transfection of synthetic miR-200 precursors into normal ovarian surface epithelial (OSE) and fallopian tube epithelial (FTE) cells confirmed reduced expression of the target genes and elevated levels of the effector genes CDH1, CRB3 and EpCAM in both normal OSE and FTE cells. However, only FTE cells had a specific induction of CA125 after miR-200 precursor transfection.

conclusionsThe activation of the miR-200 pathway may be an early event that renders the OSE and FTE cells more susceptible to oncogenic mutations and histologic differentiation. As high-grade serous ovarian carcinomas (HGSOC) usually express high levels of CA125, the induction of CA125 expression in FTE cells by miR-200 precursor transfection is consistent with the notion that HGSOC has an origin in the distal fallopian tube.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorCarcinoma in SituCell Line, TumorCystadenocarcinoma, SerousFallopian TubesFemaleGene Expression ProfilingGene Regulatory NetworksHumansMicroRNAsNeoplasm GradingNeoplasm StagingOrgan SpecificityOvarian NeoplasmsRNA InterferenceBiomarkers, TumorMicroRNAsMIRN200 microRNA, humanRNA, MessengerExpression analysisFallopian tube tumorsMicroRNAOvarian tumors

Identifiers

PMID28623900
PMCPMC5473983
OpenAlexW2626651284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.